The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas

Current Treatment Options in Oncology
Owen A O'Connor

Abstract

The elucidation of detailed new signaling pathways in normal cells and how their perturbation contributes to the development of the malignant phenotype has created innumerable venues for the development of novel drugs that can affect these targets in therapeutically meaningful ways. For example, our understanding of the complex biology underlying the ubiquitin-proteasome pathway in normal cells has recently led to the identification of specific agents capable of affecting this biology. Intuitively, one would not presume that inhibiting such a ubiquitous and essential biologic process, such as the ubiquitin-proteasome pathway, would lead to a new therapeutic strategy in cancer patients, although empirical evidence has suggested otherwise. The proteasome is a complex structure of many proteins, some of which are specific proteases, that play a critical role in regulating the balance of intracellular protein. Bortezomib, formerly known as PS-341, is a very potent and selective inhibitor of the chymotryptic-like enzymatic function residing in the 26S proteasome. Inhibition of this particular enzymatic activity has now been associated with an enormous panoply of different biologic effects, including everything from the regulation of...Continue Reading

References

Feb 24, 1995·Cell·D Thanos, T Maniatis
Jan 1, 1993·International Review of Cytology·M GrilliM J Lenardo
Jan 1, 1996·Annual Review of Immunology·A S Baldwin
Oct 4, 1996·Cell·P A Baeuerle, D Baltimore
Nov 1, 1996·Science·D J Van AntwerpI M Verma
Oct 14, 1996·Biochemical and Biophysical Research Communications·M V BlagosklonnyW S el-Deiry
Dec 6, 1996·Science·R W KingM W Kirschner
Feb 24, 1998·British Journal of Cancer·V SpataroA L Harris
Oct 28, 1998·Trends in Cell Biology·D H Lee, A L Goldberg
Dec 19, 1998·The EMBO Journal·A Ciechanover
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·V J PalombellaM B Grisham
Jan 1, 1999·Bioorganic & Medicinal Chemistry Letters·J AdamsR L Stein
Apr 8, 2000·Current Opinion in Structural Biology·P ZwicklA Steven
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S WatersF E Cotter
Jun 17, 2000·Investigational New Drugs·J AdamsP J Elliott
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·V MarshanskyJ Wu
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiSteven L Soignet
May 15, 2003·Journal of Agricultural and Food Chemistry·Varoujan A YaylayanLouis Istasse

❮ Previous
Next ❯

Citations

Dec 3, 2005·Leukemia & Lymphoma·Christian BognerThomas Decker
May 25, 2006·Seminars in Oncology Nursing·Jennifer Long, Linda Versea
Jun 30, 2005·The Annals of Pharmacotherapy·Pascal AndréJean-Eudes Fontan
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'Connor
Jan 31, 2006·Current Opinion in Clinical Nutrition and Metabolic Care·Stacey R Vlahakis, Andrew D Badley
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neeraj K AroraArnold L Potosky
Mar 14, 2008·The Journal of Biological Chemistry·Ryo Sakasai, Randal Tibbetts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.